Highlights
- The company changed its name from InhaleRx, and its ASX Code became NX1 effective 17 February 2026.
- The company had submitted AUD 2.4 million in drawdown requests but received only AUD 0.8 million.
- At the time it said it was seeking alternative funding but had no meaningful discussions underway.
- Auditor RSM flagged a material uncertainty about the company's ability to continue as a going concern.
Nexalis Therapeutics Limited (ASX:NX1), the inhaled-medicines developer formerly known as InhaleRx, spent much of 2026 dealing with the loss of the Debt Facility that was meant to fund its clinical trials. The result is a company with a completed early-stage safety study and two other programmes, but with trial work paused, a net Liability position and no replacement funder announced as of its latest disclosures.
What Nexalis does
Melbourne-based Nexalis develops drug-device combinations designed to deliver medicines by inhalation, with the aim of registering them in Australia. Its pipeline comprises IRX-211 for breakthrough cancer pain, IRX-616a for panic disorder, delivered through a pressurised metered dose inhaler, and SRX-25 for treatment-resistant depression.
The funding setback and clinical status
According to an update dated 6 July 2026, Linlithgow Family Office (LFO) cancelled the undrawn balance of its debt facility in May 2026.
Because of the funding loss, study orders with contract research organisation iNGENū CRO, a company related to chief executive Darryl Davies, were suspended for both IRX-211 and IRX-616a. The half-year report states that on 27 August 2026 the LFO facility was settled, with about AUD 642,000 outstanding cleared through the cancellation of about 38.4 million shares held by the lender and the issue of 15 million options.
The IRX-616a Phase 1 study in healthy volunteers has been completed with no serious adverse events reported, according to the company. Database lock and the clinical study report have been delayed. This is early safety and dose-ranging data, not evidence of efficacy or a step towards approval on its own.
SRX-25 remains in planning. The company has not published revised timelines.
Financial position
Current liabilities of about AUD 3.49 million exceeded current Assets by about AUD 1.88 million, and trade payables included about AUD 2.13 million owed to iNGENū CRO. Directors pointed to cost cuts, payment deferral discussions with iNGENū and Research and Development tax rebates.
Nexalis lodged its September quarter activities report and Appendix 4C on 30 October 2026, alongside a proposed issue of securities; we were unable to review those documents. A chair change was announced on 2 October, with director's interest notices on 6 October recording an initial notice for Niv Dagan and a final notice for Sean Williams.
Risks and what to watch
The central risk is funding: without new capital, the paused trials cannot resume, and any raise at current prices would be dilutive. Related-party payables to the trial contractor add complexity. Key items to watch are the details of the proposed securities issue, any new funding arrangement, the IRX-616a clinical study report, and the outcome of the IRX-211 trial review.
_11_16_2026_07_52_44_870464.jpg)




_11_16_2026_07_55_02_604226.jpg)
Please wait processing your request...